<DOC>
	<DOCNO>NCT00310882</DOCNO>
	<brief_summary>The endogenous digitalis-like compound ( DLC ) steroid hormone synthesize release adrenal gland.They integrate feed-back system Hypothalami-Pituitary-Adrenal gland axis.One remarkable function induce apoptosis malignant cell . Recently , accumulate data point possibility use synthetic DLC new anti-cancer drug . Less known endogenous metabolism compound cancer patient . Proceeding preliminary clinical data demonstrate significantly reduce DLC plasma level breast cancer patient vitro data show impaired release DLC towards stress stimuli athymic nude mouse , put hypothesis latent adrenal insufficiency low DLC level facilitate induction progression tumor disease .</brief_summary>
	<brief_title>Involvement Endogenous Digitalis-like Compounds Breast Cancer</brief_title>
	<detailed_description>To pursue question endogenous DLC metabolism cancer patient intend start measurement DLC plasma level breast cancer patient time first diagnosis compare woman benign breast disease well healthy woman . Aim Study - To evaluate basal DLC plasma concentration cancer patient time first diagnosis function HPA axis , focus breast cancer patient . - To analyze potential change HPA function , parallel , DLC plasma concentration course therapy , special respect treatment failure . - To establish potential correlation DLC plasma concentration risk factor BC . Patients Methods Patients : I . 50 - ( 100 ) patient breast cancer time first diagnosis II . 50 - ( 100 ) patient benign disease breast III . 50 - ( 100 ) woman undergo plastic surgery breast IV . 50 - ( 100 ) woman need exploration visit ambulance ( =normal population ) V. additionally group 25 - 50 student ( age 20-40 ) analyze pilot study Methods : Time-schedule Group I ( Group II . - IV . alike , accord disease and/or situation ) - Day first presentation woman clinic - Day first diagnosis , i.e . biopsy/FNA - Day start treatment : operation , chemo-/radiotherapy ( tst = 0 ) - Day + 30 , + 60 , + 90 - 6 month 1 year start treatment The Group V. ( student ) analyze special schedule , precede study 1-2 month : - 4 week important exam - day exam ( -3 day ) - day exam ( + 3 day ) - 2 week exam - 6 week exam Parameters Biochemistry ( Group I . - V. ) - Basal DLC plasma concentration - Basal serum Cortisol concentration - Basal plasma ATCH concentration - Basal Aldosterone/Renin concentration - Electrolytes ( potassium , sodium , calcium , chloride ) Pathology/Immunohistochemistry ( Group I . + II. , benign , include last 4 point ) - Tumor size - lymph node status - E/P receptor - Grade - HER2/neu - Bcl-2 - Ki67 - p53 Radiology ( Group I . ) If abdominal CT available measurement size adrenal gland Endocrinologic test ( Group I . - IV . ) - Dexamethasone-test ( low dose ) : - 2 mg Dexamethasone p.o . 24:00 - measurement Cortisol DLC 8:00 next morning - ACTH-test : - basal plasma concentration Cortisol , DLC ACTH - administration 250 µg ACTH ( Synachten® ) i.v . - measurement Cortisol DLC 30 min . 60 min . - Facultative : Metapyrone test follow time interval : 1 . Dexamethasone-test - around time first presentation ( ± 5 day ) - around time start treatment ( ± 5 day ) ; correspond time Group II.- IV . - Day + 30 , +60 , +90 - 6 month year start treatment 2 . ACTH-test - On day first presentation - On day start treatment ; correspond time Group II.- IV . - Day + 30 , +60 , +90 - 6 month one year start treatment Psychometric test Stress Evaluation ( Group I . - V. ) - day first presentation ( Students : last 2 week exam ) - end study</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Fibrocystic Breast Disease</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<criteria>first visit Breast Disease Ambulance consultation pregnancy severe heart disease ( EF &gt; 40 % ) therapy digitalis acute/chronic inflammatory disease ( e.g . RA , M. Crohn ) dysfunction HypothalamoPituitaryAdrenal system severe mental disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>digitalis like compound</keyword>
	<keyword>prognostic factor</keyword>
</DOC>